Insights

Loading spinner
Gathering insights about OYAGEN INC.

OYAGEN INC. Tech Stack

OYAGEN INC. uses 8 technology products and services including C3.js, WordPress, Cloudflare, and more. Explore OYAGEN INC.'s tech stack below.

  • C3.js
    Charting
  • WordPress
    Content Management System
  • Cloudflare
    Content Management System
  • Twemoji
    Font Scripts
  • jQuery
    Javascript Libraries
  • X-XSS-Protection
    Security
  • Google Tag Manager
    Tag Management
  • HTTP/3
    Web & Portal Technology

OYAGEN INC.'s Email Address Formats

OYAGEN INC. uses at least 1 format(s):
OYAGEN INC. Email FormatsExamplePercentage
FLast@oyageninc.comJDoe@oyageninc.com
50%
FLast@oyageninc.comJDoe@oyageninc.com
50%

Frequently Asked Questions

Where is OYAGEN INC.'s headquarters located?

Minus sign iconPlus sign icon
OYAGEN INC.'s main headquarters is located at 77 Ridgeland Rd., Henrietta, NY 14623, US. The company has employees across 1 continents, including North America.

What is OYAGEN INC.'s phone number?

Minus sign iconPlus sign icon
You can contact OYAGEN INC.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is OYAGEN INC.'s official website and social media links?

Minus sign iconPlus sign icon
OYAGEN INC.'s official website is oyageninc.com and has social profiles on LinkedInCrunchbase.

What is OYAGEN INC.'s SIC code NAICS code?

Minus sign iconPlus sign icon
OYAGEN INC.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does OYAGEN INC. have currently?

Minus sign iconPlus sign icon
As of November 2025, OYAGEN INC. has approximately 5 employees across 1 continents, including North America. Key team members include Coo: T. F.Chief Scientific Officer And Lab Director: R. B.Chief Financial Officer: K. P.. Explore OYAGEN INC.'s employee directory with LeadIQ.

What industry does OYAGEN INC. belong to?

Minus sign iconPlus sign icon
OYAGEN INC. operates in the Biotechnology Research industry.

What technology does OYAGEN INC. use?

Minus sign iconPlus sign icon
OYAGEN INC.'s tech stack includes C3.jsWordPressCloudflareTwemojijQueryX-XSS-ProtectionGoogle Tag ManagerHTTP/3.

What is OYAGEN INC.'s email format?

Minus sign iconPlus sign icon
OYAGEN INC.'s email format typically follows the pattern of FLast@oyageninc.com. Find more OYAGEN INC. email formats with LeadIQ.

How much funding has OYAGEN INC. raised to date?

Minus sign iconPlus sign icon
As of November 2025, OYAGEN INC. has raised $150K in funding. The last funding round occurred on Sep 16, 2013 for $150K.

When was OYAGEN INC. founded?

Minus sign iconPlus sign icon
OYAGEN INC. was founded in 2003.

OYAGEN INC.

Biotechnology ResearchUnited States2-10 Employees

OYAGEN is a biotechnology company formed on September 5, 2003, for the purpose of discovering, developing, and commercializing novel pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. OyaGen holds exclusive rights to important technologies originating from the University of Rochester Medical Center (URMC), the Thomas Jefferson University (TJU), and Oregon Health Science Center.

Over the past decade, a series of research advances have identified two families of related enzymes known as Editing Enzymes.  These enzymes are endogenous cellular proteins, which chemically alter RNA or DNA molecules and thereby change the genetic code. OyaGen believes that there is a significant opportunity to “harness the editing process” to create therapies for a number of disease states. OyaGen’s initial therapeutic focus is a novel approach to the treatment of Human Immunodeficiency Virus (HIV). This initial focus on HIV is driven by a series of ground breaking discoveries that:
-Identified an Editing Enzyme present in immune system 
-Determined that HIV inhibits this Editing Enzyme as a vital part of the infection cycle 
-Demonstrated that allowing this Editing Enzyme to function halts HIV 

OyaGen will pursue several proprietary assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states.
OyaGen offers method development and testing as a fee-for-service to academic/educational institutions and to industry. OyaGen staff will provide expert consulting services in assay development, biochemistry, structural biology, cell biology, virology for high throughput drug discovery, drug development as well as advice in preparing federal grants.

Section iconCompany Overview

Headquarters
77 Ridgeland Rd., Henrietta, NY 14623, US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2003
Employees
2-10

Section iconFunding & Financials

  • $150K

    OYAGEN INC. has raised a total of $150K of funding over 4 rounds. Their latest funding round was raised on Sep 16, 2013 in the amount of $150K.

  • $1M

    OYAGEN INC.'s revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $150K

    OYAGEN INC. has raised a total of $150K of funding over 4 rounds. Their latest funding round was raised on Sep 16, 2013 in the amount of $150K.

  • $1M

    OYAGEN INC.'s revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.